idarubicin; 4-methoxydaunorubicin (Idamycin)

Introduction

Tradename: Idamycin.

Indications

• used in combination treatment of acute myeloid leukemia, including FAB classification M1-M7
• non-Hodgkin's lymphoma

Powder for injection: (lyophilized) 5 mg, 10 mg.

Adverse effects

• common (> 10%)
  • infection, nausea/vomiting, alopecia, diarrhea, hemorrhage, mucositis, reddish urine, fever, headache, leukopenia, thrombocytopenia
• less common (1-10%)
  • seizure, wheezing, peripheral neuropathy
• uncommon (< 1%)
  • myocardial toxicity, congestive heart failure, acute life-threatening arrhythmias

• drug adverse effects of anthracyclines

Test interactions

• increased serum urea nitrogen, creatinine, AST, ALT, K+, uric acid

More general terms

• anthracycline

Additional terms

• daunorubicin, daunomycin; DNR (Cerubidine, DaunoXome)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=42890
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=42593
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=636362
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3685
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=444091